X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.150
+0.390 (10.37%)
Mar 9, 2026, 4:00 PM EDT - Market closed
X4 Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 363 | 125 | 140 | 121 | 64 | 105 | |
| Market Cap Growth | 349.44% | -10.81% | 16.23% | 87.36% | -38.49% | -39.22% | |
| Enterprise Value | 318 | 68 | 57 | 79 | 28 | 47 | |
| Last Close Price | 4.15 | 22.01 | 25.16 | 29.79 | 68.70 | 192.90 | |
| PS Ratio | 10.68 | 48.93 | - | - | - | 34.91 | |
| PB Ratio | 1.69 | 5.65 | 2.75 | 1.63 | 1.00 | 1.44 | |
| P/TBV Ratio | 10.42 | - | 4.16 | 2.13 | 1.37 | 2.29 | |
| EV/Sales Ratio | 9.36 | 26.73 | - | - | - | 15.63 | |
| Debt / Equity Ratio | 1.25 | 3.53 | 1.14 | 0.52 | 0.62 | 0.53 | |
| Net Debt / Equity Ratio | -0.73 | -1.08 | -1.09 | -1.12 | -0.65 | -0.55 | |
| Net Debt / EBITDA Ratio | 0.50 | 0.17 | 0.52 | 0.95 | 0.56 | 0.68 | |
| Net Debt / FCF Ratio | 0.44 | 0.18 | 0.58 | 1.08 | 0.59 | 0.67 | |
| Asset Turnover | 0.20 | 0.02 | - | - | - | 0.02 | |
| Quick Ratio | 5.27 | 3.16 | 5.02 | 5.50 | 5.89 | 6.66 | |
| Current Ratio | 5.65 | 3.41 | 5.34 | 5.76 | 6.27 | 6.97 | |
| Return on Equity (ROE) | -156.87% | -102.26% | -161.67% | -135.58% | -129.28% | -61.51% | |
| Return on Assets (ROA) | -33.54% | -60.18% | -44.38% | -40.36% | -39.24% | -26.39% | |
| Return on Capital Employed (ROCE) | -65.50% | -124.50% | -86.40% | -66.10% | -73.00% | -54.00% | |
| Earnings Yield | -26.21% | -29.93% | -72.12% | -77.78% | -137.70% | -59.33% | |
| FCF Yield | -28.42% | -104.89% | -68.84% | -63.97% | -111.04% | -57.47% | |
| Buyback Yield / Dilution | -141.76% | -13.08% | -179.91% | -146.71% | -28.25% | -74.13% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.